Supernus Pharmaceuticals, Inc. News Headlines

SUPN 
$8.94
*  
0.20
2.29%
Get SUPN Alerts
*Delayed - data as of Dec. 18, 2014  -  Find a broker to begin trading SUPN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SUPN After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Why Supernus Pharmaceuticals (SUPN) Might Be a Diamond in the Rough - Tale of the Tape
12/15/2014 8:54:00 AM - Zacks.com


Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
12/11/2014 3:20:00 PM - Zacks.com


Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
12/10/2014 2:50:00 PM - Zacks.com


Supernus Pharma Reports Paragraph IV ANDA Filing For Oxtellar XR - Quick Facts
12/10/2014 7:36:00 AM - RTT News


Why Supernus Pharmaceuticals (SUPN) Could Be Positioned for a Surge? - Tale of the Tape
12/2/2014 8:30:00 AM - Zacks.com


How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry - Tale of the Tape
12/1/2014 9:01:00 AM - Zacks.com


Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
11/24/2014 6:00:00 PM - Zacks.com


Third Quarter Was Robert Bruce's Busiest in 2014
11/21/2014 5:09:44 PM - GuruFocus


Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% - Tale of the Tape
11/19/2014 9:32:00 AM - Zacks.com


Supernus Pharma Posts Profit In Q3, Ups Full Year Revenue View; Stock Climbs
11/11/2014 11:41:00 PM - RTT News


Supernus Pharma Posts Profit In Q3, Ups Full Year Revenue View; Stock Climbs
11/11/2014 11:41:00 PM - RTT News


SUPN Revises Revenue Outlook Upward, EVDY Fit And Fine, NASDAQ Warning For ACST
11/11/2014 10:40:00 PM - RTT News


SUPN Revises Revenue Outlook Upward, EVDY Fit And Fine, NASDAQ Warning For ACST
11/11/2014 10:40:00 PM - RTT News


After-Hours Earnings Report for November 11, 2014 : FOSL, YY, TAHO, HMIN, LXFT, STKL, AERI, MGNX, SUPN, PFIE, FATE, CLSN
11/11/2014 2:00:03 PM - NASDAQ.com News


Supernus' Trokendi XR Faces Generic Threat from Zydus - Analyst Blog
10/15/2014 5:45:00 PM - Zacks.com


Actavis in Acquisition Mode, Durata Deal to Boost Portfolio - Analyst Blog
10/7/2014 4:42:00 PM - Zacks.com


Supernus Up, Files Lawsuit against Actavis for Trokendi XR - Analyst Blog
10/6/2014 1:20:00 PM - Zacks.com


Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
9/25/2014 5:19:00 PM - Zacks.com


Supernus Confirms 2014 Outlook, Epilepsy Products in Focus - Analyst Blog
9/23/2014 3:55:00 PM - Zacks.com


Sector Update: Health Care Stocks Still Struggling; Supernus Pharmaceuticals Gains After Saying It Won't Need More Funding
9/23/2014 12:24:29 PM - MT Newswires


Sector Update: Health Care
9/23/2014 12:13:13 PM - MT Newswires


Others Overlooked Supernus Pharmaceuticals (SUPN), Should You Buy It Now? - Tale of the Tape
9/10/2014 7:47:00 AM - Zacks.com


Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog
8/22/2014 3:55:00 PM - Zacks.com


Should You Get Rid of Corium International (CORI) Now? - Tale of the Tape
8/20/2014 7:55:00 AM - Zacks.com


Supernus's SPN-810 Gets Fast Track Status for ADHD - Analyst Blog
8/18/2014 12:30:00 PM - Zacks.com